Clinical trials: Multiple Primary Neoplasm
Cystic Fibrosis, Primary Ciliary Dyskinesia
Bacteriological Link Between Upper and Lower Airways in Cystic Fibrosis and Primary Ciliary Dyskinesia
Cytobacteriological examination of sputum and bacteriological sampling in the middle meatus.
- Trial name
- BAVASI (NCT03494894)
- Testing
- Middle meatus aspirations and sputum
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Epilepsy, Focal Cortical Dysplasia
Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery
Refractory epilepsy, meaning epilepsy that no longer responds to medication, is a common neurosurgical indication in children. In such cases, surgery is the treatment of choice.
- Conditions
- Epilepsy, Focal Cortical Dysplasia, Tuberous Sclerosis, Hemimegalencephaly
- Trial name
- NCT04344626
- Testing
- Intra-operative brain tonometry
- Where
- 2 sites in United States, Canada
- Sponsor
- University of California, Los Angeles
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004132
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Primary Hemophagocytic Lymphohistiocytosis
A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients
The goal of this post-authorization study is to describe safety and efficacy of emapalumab in treatment experienced Chinese patients with pHLH.
- Trial name
- NCT05744063
- Testing
- Emapalumab-Lzsg 5 MG/ML [Gamifant]
- Where
- 7 sites in China
- Volunteers
- 13 people
- Sponsor
- Swedish Orphan Biovitrum
Primary Ciliary Dyskinesia, Kartagener Syndrome
Swiss Primary Ciliary Dyskinesia Registry
The Swiss Primary Ciliary Dyskinesia (PCD) Registry is a national patient registry that collects information on diagnosis, symptoms, treatment and follow-up of patients with PCD in Switzerland and provides data for national and…
- Trial name
- CH-PCD (NCT03606200)
- Where
- Switzerland
- Volunteers
- 800 people
- Sponsor
- University of Bern
Primary Ciliary Dyskinesia, Kartagener Syndrome
International Primary Ciliary Dyskinesia Cohort
The iPCD Cohort is an international cohort that assembles available retrospective datasets and prospectively newly collected clinical and diagnostic data from patients suffering from primary ciliary dyskinesia (PCD) worldwide, to…
- Trial name
- iPCD (NCT03517865)
- Where
- Switzerland
- Volunteers
- 3,400 people
- Sponsor
- University of Bern
Spontaneous Pneumothorax
Spontaneous Pneumothorax in Children
The objective of this multi-center, non-randomized, prospective pilot study is to examine the rate of successful primary spontaneous pneumothorax (PSP) resolution using the simple aspiration technique.
- Trial name
- NCT02573285
- Testing
- Simple Aspiration, Surgeon Preference
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1
Baby Detect : Genomic Newborn Screening
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions.
- Conditions
- Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1, Phosphoglucomutase 1 Deficiency, Maturity Onset Diabetes of the Young
- Trial name
- BabyDetect (NCT05687474)
- Where
- Belgium
- Volunteers
- 6,824 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Liege
Brain Neoplasms
Phase II Randomized Study of Stereotactic Radiosurgery Plus Fractionated Whole-Brain Radiotherapy Vs Fractionated Whole-Brain Radiotherapy Alone for Multiple Primary or Metastatic Brain Tumors
OBJECTIVES: I. Evaluate whether stereotactic radiosurgery provides local control at multiple sites in patients with primary or metastatic brain tumors, controlled systemic disease, and preserved neurologic function. II.
- Trial name
- NCT00004659
- Testing
- irradiation, radiosurgery
- Volunteers
- 40 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004165
- Testing
- filgrastim, melphalan, peripheral blood stem cell transplantation
- Where
- United States
- Sponsor
- Northwestern University
Primary Ciliary Dyskinesia
Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide
Background: Primary ciliary dyskinesia (PCD) is a rare genetic disease characterised by recurrent respiratory infections and subfertility due to dysfunction of cilia (brushes) of the lining cells.
- Trial name
- NCT00739817
- Where
- Israel
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Ziv Hospital
Primary Ciliary Dyskinesia
Muscle Function, Exercise Capacity and Physical Activity Level in Primary Ciliary Dyskinesia and Kartagener Syndrome
Studies evaluating respiratory and peripheral muscle functions in PCD patients and comparing them with healthy children are limited in the literature.
- Trial name
- NCT05816876
- Where
- Turkey (Türkiye)
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Gazi University
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Myeloproliferative Disorders, Leukemia
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
RATIONALE: Giving total marrow and total lymph node irradiation together with low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00800150
- Testing
- fludarabine phosphate, melphalan, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous sclerosis complex (TSC) who experience seizures.
- Trial name
- EpiCom (NCT05864846)
- Testing
- Cannabidiol Oral Solution [Epidiolex]
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 79 people
- Sponsor
- Jazz Pharmaceuticals
Primary Ciliary Dyskinesia, Kartagener Syndrome
The Ear-Nose-Throat (ENT) Prospective International Cohort of PCD Patients (EPIC-PCD)
The Ear-Nose-Throat (ENT) Prospective International Cohort of patients with Primary Ciliary Dyskinesia (EPIC-PCD) is a prospective observational clinical cohort study, set up as a multinational multi-centre study.
- Trial name
- EPIC-PCD (NCT04611516)
- Where
- Switzerland
- Volunteers
- 1,000 people
- Sponsor
- University of Bern
Ciliary Motility Disorders, Primary Ciliary Dyskinesia
Genotype/Phenotype Correlation With Focus on Lung Function in Primary Ciliary Dyskinesia (PCD)
Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder characterized by dysfunction of motile cilia associated with recurrent infections of the airways, laterality defects (Situs inversus totalis in about 50% of cases) and…
- Trial name
- LuFu_PCD (NCT04717115)
- Testing
- Genetic diagnosis
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- University Hospital Muenster
Hiv
Engaging Men Through HIV Self-Testing With Differentiated Care to Improve ART Initiation and Viral Suppression Among Men in Malawi
Men in sub-Saharan Africa who test HIV-positive continue to have poor ART initiation and retention outcomes. The proposed project will test a home-based ART intervention for men who are living with HIV compared to facility-based…
- Trial name
- NCT04858243
- Testing
- Home-Based ART, Facility-Based ART
- Where
- Malawi
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Parathyroid Cancer, Primary Hyperparathyroidism
Natural History Study of Parathyroid Disorders
Background: Parathyroid disorders are very common in the general population and include disorders of parathyroid excess, deficiency, or defects in parathyroid hormone (PTH) signaling.
- Conditions
- Parathyroid Cancer, Primary Hyperparathyroidism, Pseudohypoparathyroidism, Inheritable Bone Diseases
- Trial name
- NCT04969926
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Evaluation of the Impact of the MSProgress Quality Approach Support Tool on the Evolution of the Indicators Chosen by the MSPs in Comparison With Standard Care
Impact Study of the MSProgress Quality Approach Support Tool for Healthcare Centers Multiprofessionals (MSP) of the AUvergne-Rhône-Alpes Region Using a Mixed Method Evaluating the Evolution of Indicators Chosen by MSPs and Their Use in Multi-professional Teams
Since 2008, the Federation of Health Centers and Coordinated Practice in Auvergne Rhône-Alpes (FemasAURA\&Co) has been supporting healthcare centers Multiprofessionals (MSPs) in their development in the Auvergne-Rhône-Alpes…
- Trial name
- QualiMSP'AURA (NCT07179289)
- Testing
- Provision of the MSProgress quality approach support tool
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand